Deutsche Bank Downgrades McKesson (MCK) to Hold
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Deutsche Bank downgraded McKesson (NYSE: MCK) from Buy to Hold with a price target of $153.00 (from $196.00). Analyst George Hill expressed fears of a price war in drug wholesaling.
"MCK reported F2Q results below consensus, but it was the company's outlook and commentary that drive our ratings change. MCK reported F2Q EPS of $2.94 (-7%), below the Street's $3.04. The company lowered its F17 guidance range by $1.10 to $12.35-$12.85, which will now likely be down vs F16. We had recently cut our numbers citing the risks from slower brand drug price inflation, but MCK noted increased sell side margin pressure was more to blame. While we hate downgrading a stock on a miss/steep decline, we do not believe this was the clearing event necessary to create a bottom for MCK shares and move to Hold on valuation and a lack of earnings visibility," said Hill.
Shares of McKesson closed at $160.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Skyworks Solutions (SWKS) PT Raised to $105 at Oppenheimer Following 1Q Report
- Signet Jewelers (SIG) May Be Close To Selling Credit Business, Likely Positive For Stock - Northcoast Research
- BofA/Merrill Lynch Upgrades CF Industries (CF) to Buy, Says "Consensus Estimates Now Beatable"
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Downgrades
Related EntitiesDeutsche Bank, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!